Analyst Reco. Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Delayed Nasdaq Other stock markets 03:47:59 2024-04-16 pm EDT			5-day change	1st Jan Change
41.4 ^USD	-0.72%		-1.71%	-2.33%

Mar. 25	Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	MT
Mar. 04	Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,057,890, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25	MT
Mizuho Raises Price Target on Cerevel Therapeutics to $45 From $25 to Reflect Sale Price to AbbVie, Keeps Neutral Rating	Feb. 15	MT
JPMorgan Raises Price Target on Cerevel Therapeutics Holdings to $45 From $25, Keeps Neutral Rating	Dec. 28	MT
Jefferies Downgrades Cerevel Therapeutics to Hold From Buy, Adjusts Price Target to $45 From $40	Dec. 22	MT
TD Cowen Downgrades Cerevel Therapeutics to Market Perform From Outperform, Price Target is $45	Dec. 08	MT
HC Wainwright Downgrades Cerevel Therapeutics to Neutral From Buy, Raises Price Target to $45 From $41	Dec. 07	MT
Are rate cuts are coming early next year?	Dec. 07
Cantor Fitzgerald Downgrades Cerevel Therapeutics to Neutral From Overweight, Raises Price Target to $45 From $38	Dec. 07	MT
Piper Sandler Downgrades Cerevel Therapeutics to Neutral From Overweight, Price Target is $45	Dec. 07	MT
Piper Sandler Starts Cerevel Therapeutics Holdings at Overweight, $33 Price Target	23-09-28	MT
Mizuho Cuts Price Target on Cerevel Therapeutics to $25 From $29, Keeps Neutral Rating	23-08-07	MT
Morgan Stanley Adjusts Price Target on Cerevel Therapeutics to $42 From $46, Maintains Overweight Rating	23-08-03	MT
HC Wainwright Adjusts Price Target on Cerevel Therapeutics to $41 From $45, Maintains Buy Rating	23-08-03	MT
BofA Securities Downgrades Cerevel Therapeutics Holdings to Neutral From Buy, Adjusts Price Target to $31 From $36	23-08-03	MT
Berenberg Bank Adjusts Cerevel Therapeutics Price Target to $24 From $22, Maintains Hold Rating	23-08-03	MT
Goldman Sachs Adjusts Price Target on Cerevel Therapeutics to $30 From $31, Keeps Neutral Rating	23-05-23	MT
Mizuho Securities Adjusts Cerevel Therapeutics Price Target to $29 From $26, Maintains Neutral Rating	23-05-08	MT
Wells Fargo Upgrades Cerevel Therapeutics Holdings to Overweight From Equalweight, Price Target is $30	23-05-04	MT
TD Cowen Initiates Cerevel Therapeutics Holdings at Outperform	23-04-10	MT
JPMorgan Downgrades Cerevel Therapeutics Holdings to Neutral From Overweight, Adjusts Price Target to $29 From $40	23-03-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cerevel Therapeutics Holdings, Inc.

Equities

CERE

US15678U1280

Analyst Reco.

Filters